Company intelligence / Profile preview

Epeius Biotechnologies

San Marino, California, United Statesbiospace.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Rexin-G has demonstrated significant anti-tumor activity and safety across several refractory cancers. It has achieved FDA Orphan Drug Status and Fast Track Designation for pancreatic cancer, with accelerated approval in the Philippines. Clinical trials have shown efficacy as a single agent with minimal toxicity.

Therapeutic areas: HematologyOncology
Modalities: Gene therapyNanoparticleViral vector-based gene delivery
Industry: Biotech

Drug pipeline

2 assets

deltarex-g

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Not specified; company mentions strategic partnerships sought or possible in oncology, immunology, cardiovascular, ocular/wound healing applications.

Beyond the preview

Go deeper on Epeius Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epeius Biotechnologies.

Explore the full profile